Clinical Trial Detail

NCT ID NCT03259425
Title Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Utah
Indications

melanoma

Therapies

Canerpaturev + Nivolumab

Age Groups: adult senior

No variant requirements are available.